| Sanjay Nayak |
Sanjay Nayak is currently the Chief Strategy Officer at Ocular Therapeutix, Inc. He holds a doctorate degree from Drexel University and an undergraduate degree from The Grant Government Medical College. |
| Christopher G. White |
Christopher G. White's current job is Chief Business Officer at Ocular Therapeutix, Inc. His former jobs include being a Partner-Pharmaceutical & Medical Products Practice at Accenture Ltd. from 2005 to 2007, VP, Partner-Pharmaceuticals & Healthcare Practice at A.T. Kearney, Inc. from 1998 to 2005, Chief Business Officer & Senior Vice President at AMAG Pharmaceuticals, Inc. from 2007 to 2014, Chief Operating Officer at Silver Creek Pharmaceuticals, Inc., Chief Business Officer at Entasis Therapeutics, Inc., and President & Chief Operating Officer at Sofregen Medical, Inc. Mr. White holds an MBA from The Trustees of Columbia University in The City of New York and an undergraduate degree from Tufts University. |
| Peter K. Kaiser |
Peter K. Kaiser is the founder of SKS Ocular LLC. He currently holds the position of Director-DOCTR at Cole Eye Institute. Additionally, he is the Chief Development Officer at Ocular Therapeutix, Inc. starting in 2024. He is also a Member of Macula Society, American Ophthalmological Society, and The Retina Society. Previously, he worked as the Senior Vice President-Product Development at Ohr Pharmaceutical, Inc. Dr. Kaiser's education includes an undergraduate degree from Harvard Medical School, a doctorate degree from Harvard Medical School, and an undergraduate degree from Harvard College. |
| Pravin U. Dugel |
Pravin U. Dugel is the founder of Spectra Eye Institute. He currently holds multiple positions, including Chairman, President & Chief Executive Officer at Ocular Therapeutix, Inc. since 2024, and Director at ORBIS International, Inc. since 2017. He is also a Director at the American Society of Retinal Specialists, EURETINA – Europäische Gesellschaft für Netzhautspezialisten, and the University of Southern California, where he is a Professor. In his former positions, he served as Chairman-Retina Subspecialty Day Board at the American Academy of Ophthalmology, Inc., Director at Aerpio Therapeutics, Inc., President & Director at IVERIC bio, Inc. from 2023 to 2023, Independent Director at Aerpio Pharmaceuticals, Inc. from 2017 to 2021, Independent Non-Executive Director at Oculis Holding AG from 2020 to 2024, and Managing Partner at Retinal Consultants of Arizona Ltd. from 1994 to 2019. He also held positions as Managing Partner at Retinal Research Institute LLC, Professor at Keck School of Medicine of USC, and Clinical Professor at Usc Roski Eye Institute. Dr. Dugel completed his undergraduate degree at The Trustees of Columbia University in The City of New York and his graduate degree at David Geffen School of Medicine. |
| Donald Notman |
Donald Notman is currently the COO, Chief Financial & Accounting Officer at Ocular Therapeutix, Inc. He previously worked as the Managing Director & Head-Private Capital Markets at Leerink Partners LLC and as the Chief Financial Officer & Senior Vice President at Thrasos Therapeutics, Inc. Mr. Notman completed his undergraduate degree at Middlebury College and holds an MBA from the Tuck School of Business at Dartmouth. |
| Jeffrey S. Heier |
Jeffrey S. Heier is currently the Co-Director-Vitreoretinal Fellowship at Tufts University School of Medicine, the Chief Scientific Officer at Ocular Therapeutix, Inc., and a Member of the Macula Society. He previously served as the Secretary & Director of The Retina Society, Director & Member of the American Society of Retinal Specialists, Co-President & Medical Director of Ophthalmic Consultants of Boston, Secretary-Online Education at the American Academy of Ophthalmology, Inc., President-Elect of the New England Ophthalmological Society, Partner at Boston Eye Surgery & Laser Center Trust and Cape Cod Eye Surgery & Laser Center, and President of the Center For Eye Research & Education Foundation. He obtained his undergraduate degree from Brandeis University and his doctorate from Boston University School of Medicine. |
| Steve Meyers |
Steve Meyers is currently the Chief Commercial Officer at Ocular Therapeutix, Inc. He previously worked as the Vice President-Sales at Flexion Therapeutics, Inc. Mr. Meyers completed his undergraduate degree at Louisiana State University. |
| Karen-Leigh Edwards |
Karen-Leigh Edwards is currently the Senior Vice President-Technical Operations at Ocular Therapeutix, Inc. She previously worked as the Head-External Manufacturing & Operations at Alexion Pharmaceuticals, Inc. Edwards has a graduate degree from the University of London, a doctorate from the University of Kansas, and an undergraduate degree from the University Of The West Indies. She also holds an MBA from the MIT Sloan School of Management. |
| Nadia K. Waheed |
Nadia K. Waheed is currently the Director at Bionic Sight LLC, the Director at Boston Image Reading Center LLC, and the Chief Medical Officer at Ocular Therapeutix, Inc. She previously worked as the Chief Medical Officer at Beacon Therapeutics (USA), Inc. and Gyroscope Therapeutics Holdings Plc. She holds a graduate degree from Harvard T.H. Chan School of Public Health and a doctorate degree from Aga Khan University. |
| Charles M. Warden |
Charles M. Warden is the founder of Aquahealth, Inc., Aquea Health, Inc. He currently holds the position of Lead Independent Director at Ocular Therapeutix, Inc. since 2008. He is also a Director at WaveTec Vision Systems, Inc., ForSight VISION4, Inc., Ceterix Orthopaedics, Inc., IanTech, Inc., and serves as an Advisor at The Innovation Factory LLC. In his former positions, he served as a Director at LipoSonix, Inc., AcuFocus, Inc., Confluent Surgical, Inc., Halscion, Inc., ForSight VISION5, Inc., Cotera, Inc., Concentric Medical, Inc., and Celula, Inc. He was also a Managing Director at Versant Venture Management LLC and a Director at The Foundry LLC, ForSight Labs LLC, and Twelve, Inc. Prior to that, he worked as an Associate at Boston Capital Ventures. He started his career as a General Partner at SV Health Investors LLC from 1996 to 2004. Mr. Warden completed his undergraduate studies at Beloit College and holds an MBA from Harvard Business School. |
| Peter Jarrett |
Peter Jarrett is currently the Chief Technical Officer at Ocular Therapeutix, Inc. He previously worked as the Head of Research & Development at Wyeth Holdings LLC. From 1993 to 2001, he served as the Vice President of Research & Development at Focal, Inc. Following that, he held the position of Vice President of Biomaterials R&D at Genzyme Corp. from 2001 to 2007. Dr. Jarrett obtained his undergraduate degree from Connecticut College and his doctorate from The Institute of Materials Science. |
| Richard L. Lindstrom |
Richard L. Lindstrom founded Phillips Eye Institute in 1979, where he worked as Partner from 2009 to 2010 and Minnesota Eye Consultants PA in 1983, where he is working as Chief Executive Officer. Dr. Lindstrom also founded Surface Ophthalmics, Inc., where he is working as Chairman. Dr. Lindstrom also currently works at Lindstrom Restoration, as Chairman, President & Chief Executive Officer from 1994, American Society of Cataract & Refractive Surgery Foundation, as Chairman, AcuFocus, Inc., as Director from 2007, and various other companies. Dr. Lindstrom also formerly worked at Vision Foundation, Inc., as Chairman, Laser Vision Centers, Inc., as Director, Cryocon, Inc., as Director in 2003, and various other companies. Dr. Lindstrom received his undergraduate degree from The College of Liberal Arts at the University of Minnesota and doctorate degree in 1972 from The College of Liberal Arts at the University of Minnesota. |
| Merilee Raines |
Merilee Raines currently works at Watts Water Technologies, Inc., as Independent Director from 2011, Ocular Therapeutix, Inc., as Independent Director from 2021, TransMedics, Inc., as Director, TransMedics Group, Inc., as Independent Director from 2021, and Excelitas Technologies Corp., as Director from 2018. Ms. Raines also formerly worked at Benchmark Electronics, Inc., as Independent Director from 2018 to 2021, Affymetrix, Inc., as Independent Director from 2015 to 2016, Aratana Therapeutics, Inc., as Independent Director from 2014 to 2019, PetVet Care Centers LLC, as Director from 2016 to 2018, Dead River Co., as Director from 2018 to 2021, and IDEXX Laboratories, Inc., as Chief Financial Officer & Executive Vice President from 2012 to 2013. Ms. Raines received her undergraduate degree in 1977 from Bowdoin College and Masters Business Admin degree in 1979 from The University of Chicago. |
| Seung Suh Hong |
Seung Suh Hong is currently the Vice Chairman at Novalgen Ltd. and Novelgen Co. Ltd(South Korea). He is also an Independent Director at Ocular Therapeutix, Inc. Previously, he served as the President & Chief Executive Officer at Celltrion Healthcare Co., Ltd. from 2014 to 2015. He was also the President at Celltrion Healthcare Japan KK from 2016 to 2019. Additionally, he held the position of President & Chief Operating Officer at Cellemedy Co., Ltd. Dr. Hong completed his undergraduate, graduate, and doctorate degrees at Seoul National University. |
| Leslie J. Williams |
Leslie J. Williams is the founder of ImmusanT, Inc. (founded in 2010) and hC Bioscience, Inc. (founded in 2021). At ImmusanT, Inc., Ms. Williams held the title of President, Chief Executive Officer & Director from 2010 to 2019. At hC Bioscience, Inc., Ms. Williams currently holds the title of President, Chief Executive Officer & Director. Ms. Williams's current job(s) include being an Independent Director at Ocular Therapeutix, Inc. since 2019, Executive Director at UI College of Pharmacy since 2015, Operating Partner at Accelerator Services Corp since 2020, and a member of the Board of Advisors at Life Science Cares, Inc.Ms. Williams's former job(s) include being the President & Chief Executive Officer of Ventaira Pharmaceuticals, Inc. from 2003 to 2008, Director at Hepregen Corp. from 2008 to 2014, Marketing Director at INO Therapeutics LLC, Director at CDI Bioscience, Inc. from 2006 to 2011, Director at The Capital Network, Inc. from 2009 to 2016, Lead Independent Director at Windtree Therapeutics, Inc. from 2021 to 2024, and holding positions at Merck & Co., Inc., BVP Partners LLC, Inomax LLC (Florida), Datex-Ohmeda, Inc., and GlaxoSmithKline LLC. Ms. Williams's education history includes an undergraduate degree from the University of Iowa and an MBA from Olin Business School, conferred in 1995. |
| Adrienne L. Graves |
Adrienne L. Graves founded Santen, Inc. in 1995, where she worked as President & Chief Executive Officer from 2002 to 2010 and Glaucoma Research Foundation in 2007, where she is working as Director from 2007. Dr. Graves also founded Ophthalmic Women Leaders. Dr. Graves also currently works at Retinal Degeneration Fund, as Chairman from 2022, Ocular Therapeutix, Inc., as Independent Director from 2023, Nicox Ophthalmics, Inc., as Director from 2014, and various other companies. Dr. Graves also formerly worked at IVERIC bio, Inc., as Chairman from 2021 to 2023, Akorn, Inc., as Independent Director from 2012 to 2020, TearLab Corporation, Inc., as Independent Director from 2005 to 2018, and various other companies. Dr. Graves received her undergraduate degree from Brown University and doctorate degree from the University of Michigan. |
